Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,739 stopped studies mapped to Lymphoma and descendants · 89% state a reason
Over the 1,739 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00504205 | MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma | N/A | terminated | Jul 19, 2007 | Astex Pharmaceuticals, Inc. | Withdrawn as trial was never activated by SuperGen | Other (stated, no rule matched) |
| NCT00513318 | Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients… | — | terminated | Aug 8, 2007 | University of California, San Francisco | Insufficient enrollment to justify keeping open. | Enrollment / accrual |
| NCT01671813 | Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly | N/A | withdrawn | Aug 24, 2012 | H. Lee Moffitt Cancer Center and Research Institute | Terminated by pharmaceutical sponsor - no accrual | Enrollment / accrual |
| NCT00301860 | Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young… | N/A | terminated | Mar 13, 2006 | University of California, San Francisco | lack of efficacy | Efficacy / futility |
| NCT00003502 | Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma | Phase 2 | withdrawn | Jan 27, 2003 | Burzynski Research Institute | not stated | Not stated |
| NCT00003505 | Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma | Phase 2 | withdrawn | Jan 27, 2003 | Burzynski Research Institute | not stated | Not stated |
| NCT00085345 | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or… | Phase 2 | withdrawn | Jun 11, 2004 | Oncotherapeutics | not stated | Not stated |
| NCT00112879 | Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With… | Phase 2 | withdrawn | Jun 3, 2005 | The Cleveland Clinic | not stated | Not stated |
| NCT00275106 | Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With… | Phase 3 | terminated | Jan 11, 2006 | Children's Cancer and Leukaemia Group | Withdrawn due to an excess of toxic deaths | Other (stated, no rule matched) |
| NCT00377104 | Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small… | Phase 1 | terminated | Sep 15, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00079443 | FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With… | Phase 2 | terminated | Mar 10, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00609817 | Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma | Phase 1 | terminated | Feb 7, 2008 | La Jolla Pharmaceutical Company | Lack of funding | Funding |
| NCT00776802 | GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory…(GCS-100LE) | Phase 1 / Phase 2 | withdrawn | Oct 21, 2008 | La Jolla Pharmaceutical Company | Lack of funding | Funding |
| NCT01617213 | Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma(AMM-2011) | Phase 2 | terminated | Jun 12, 2012 | University of Virginia | Study is no longer needed as recent data have answered the primary hypotheses for this study. | Other (stated, no rule matched) |
| NCT00009984 | Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer | Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01238146 | Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With… | Phase 1 / Phase 2 | withdrawn | Nov 10, 2010 | National Cancer Institute (NCI) | No patients accrued. | Enrollment / accrual |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With… | Phase 1 | terminated | Feb 8, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00493454 | Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas | Phase 2 | terminated | Jun 28, 2007 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
| NCT00126191 | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma | Phase 2 | terminated | Aug 3, 2005 | Dana-Farber Cancer Institute | closed due to slow accrual | Enrollment / accrual |
| NCT00354185 | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic… | Phase 1 | terminated | Jul 20, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00801918 | Denileukine Diftitox for Relapsed ALCL | Phase 2 | withdrawn | Dec 4, 2008 | Columbia University | Lack of funding | Funding |
| NCT00558727 | Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | Phase 1 | terminated | Nov 15, 2007 | Spectrum Pharmaceuticals, Inc | not stated | Not stated |
| NCT00393380 | Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an… | Phase 2 | terminated | Oct 27, 2006 | The Emmes Company, LLC | Study stopped because of toxicity concerns. | Safety / toxicity |
| NCT00899951 | Studying Fentanyl in Patients With Cancer | — | terminated | May 12, 2009 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | poor accrual | Enrollment / accrual |
| NCT00006708 | S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With… | Phase 3 | terminated | Mar 17, 2004 | SWOG Cancer Research Network | lack of accrual | Enrollment / accrual |
| NCT00968396 | Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts | Phase 2 | withdrawn | Aug 31, 2009 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00499668 | Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients… | N/A | withdrawn | Jul 11, 2007 | Vanderbilt-Ingram Cancer Center | slow accrual | Enrollment / accrual |
| NCT00087009 | Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive… | Phase 1 | terminated | Jul 12, 2004 | Memorial Sloan Kettering Cancer Center | Lack of Accrual | Enrollment / accrual |
| NCT01179490 | Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma | Phase 2 | terminated | Aug 11, 2010 | SymBio Pharmaceuticals | not stated | Not stated |
| NCT00003435 | Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood… | Phase 1 | withdrawn | Jun 9, 2004 | Duke University | not stated | Not stated |
| NCT01667289 | Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma | Phase 2 | terminated | Aug 17, 2012 | Fudan University | unexpected high grade of mucositis observed | Other (stated, no rule matched) |
| NCT01680796 | Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple… | Phase 1 | withdrawn | Sep 7, 2012 | University of Florida | The target drug, dovitinib, failed as a single agent in prior studies in patients with heavily… | Other (stated, no rule matched) |
| NCT01101412 | Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing… | Phase 1 / Phase 2 | withdrawn | Apr 12, 2010 | M.D. Anderson Cancer Center | Study was not opened. | Other (stated, no rule matched) |
| NCT00006220 | Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer… | Phase 1 / Phase 2 | terminated | May 20, 2004 | Washington University School of Medicine | Study drug became commercially available. | Other (stated, no rule matched) |
| NCT00005786 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia | N/A | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00452127 | A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or… | Phase 1 / Phase 2 | terminated | Mar 27, 2007 | Genentech, Inc. | not stated | Not stated |
| NCT01266811 | A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in… | Phase 3 | withdrawn | Dec 24, 2010 | Centocor, Inc. | Study canceled based on results of different study with similar hypothesis, investigational agent,… | Other (stated, no rule matched) |
| NCT00015912 | Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory… | Phase 2 | terminated | Oct 15, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00060112 | Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma | Phase 1 | terminated | May 7, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00005090 | S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in… | Phase 3 | terminated | Aug 28, 2003 | SWOG Cancer Research Network | poor accrual | Enrollment / accrual |
| NCT00086840 | CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Phase 2 | terminated | Jul 12, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00005950 | 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell… | Phase 2 | terminated | Apr 20, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00005982 | 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma | Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00036855 | Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00030381 | Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis | Phase 1 | terminated | Sep 17, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00052377 | Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides | Phase 1 / Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00087191 | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or… | N/A | terminated | Jul 12, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00101244 | SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's… | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | Administratively Complete. | Other (stated, no rule matched) |
| NCT00003613 | O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01234974 | IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus | Phase 2 | withdrawn | Nov 4, 2010 | Milton S. Hershey Medical Center | Study never undertaken | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 2, 2013source: clinicaltrials